YOU STOPPED AT: “ CURRENT STATUS (as of your question): ├─ Time since surgery: ~9.5 months ├─ PSA status:...

COMPLETING YOUR ACCURATE CASE SUMMARY

Let me finish the comprehensive correction and then address what comes next for your surveillance and monitoring.

---

YOUR COMPLETE PATHOLOGY SUMMARY - ACCURATELY STATED

What Your Pathology Report Tells Us

TUMOR CHARACTERISTICS:
Gleason Score: 7 (3+4)
├─ Grade Group 2 (Intermediate risk)
├─ 70% well-differentiated (Gleason 3)
├─ 30% moderately differentiated (Gleason 4)
├─ NOT high-grade (would be 8-10)
└─ Intermediate aggressiveness

Stage: pT2 (Pathologic Tumor Stage 2)
├─ Cancer confined to prostate
├─ NO extraprostatic extension
├─ NO invasion beyond prostate capsule
├─ NO seminal vesicle involvement
├─ NO bladder neck involvement
└─ Localized disease (best-case scenario for stage)

Cancer Volume:
├─ <5% in each lobe
├─ Minimal disease burden
├─ Not extensive involvement
└─ Favorable for prognosis

MARGIN STATUS (Critical for recurrence risk):
Negative margins:
├─ Circumferential (peripheral) margins: NEGATIVE
├─ Bladder neck margin: NEGATIVE
├─ Vas deferens margin: NEGATIVE
└─ These are all clear

Focal positive margin:
├─ Location: Apex (tip of prostate)
├─ Extent: Focal (small area)
├─ Meaning: Cancer cells reached the surgical edge at apex
├─ Significance: Increases recurrence risk vs. negative margins
└─ But: Better than extensive positive margins

AGGRESSIVE FEATURES:
Perineural invasion: PRESENT
├─ Cancer cells invading nerve sheaths
├─ Associated with higher recurrence risk
├─ Indicates more aggressive biology
└─ Increases need for surveillance

Lymphovascular invasion: ABSENT
├─ Cancer NOT invading blood/lymph vessels
├─ Favorable finding
├─ Suggests lower metastatic potential
└─ Good prognostic sign

LYMPH NODE STATUS:
Nx (not assessed)
├─ Pelvic lymph nodes were NOT removed
├─ Cannot determine if lymph node involvement
├─ Standard for low-intermediate risk cases
├─ Would only be assessed if high-risk features present
└─ Your case didn't warrant lymph node dissection

SEMINAL VESICLES:
Status: NEGATIVE
├─ No cancer involvement
├─ Favorable finding
├─ Reduces recurrence risk
└─ Good prognostic indicator

Your Risk Profile Summary

FAVORABLE FACTORS (lower recurrence risk):
✓ pT2 stage (localized disease)
✓ <5% cancer in each lobe (minimal disease)
✓ No extraprostatic extension
✓ No seminal vesicle involvement
✓ No bladder neck involvement
✓ No lymphovascular invasion
✓ Negative margins at 3 of 4 locations
✓ Excellent PSA response to surgery (5.14 → 0.009)
✓ Undetectable PSA at 9.5 months post-op

UNFAVORABLE FACTORS (higher recurrence risk):
✗ Gleason 7 (3+4) - intermediate grade
✗ 30% Gleason 4 component - poorly differentiated
✗ Perineural invasion present
✗ Focal positive margin at apex
✗ Pre-op PSA 5.14 ng/mL - moderate elevation

NET ASSESSMENT:
├─ Overall risk category: INTERMEDIATE
├─ 5-year biochemical recurrence: 20-30%
├─ 5-year cancer-free survival: 70-80%
├─ 10-year biochemical recurrence: 30-40%
├─ 10-year cancer-free survival: 60-70%
└─ Cannot predict individual outcome

---

WHAT HAPPENS NOW - YOUR SURVEILLANCE PLAN

According to NCCN Guidelines for Post-Prostatectomy Surveillance

Your current status:

✓ Undetectable PSA at 9.5 months post-op
✓ No clinical evidence of recurrence
✓ Excellent surgical response
✓ Ready for long-term surveillance protocol

Recommended PSA Monitoring Schedule

Based on NCCN Guidelines for Intermediate-Risk Prostate Cancer:

MONTHS 0-12 POST-OP (You are here):
├─ PSA testing: Every 3 months
├─ Your schedule:
│  ├─ [date removed]: 0.009 ng/mL ✓ (completed)
│  ├─ [date removed]: Expected (3 months)
│  ├─ [date removed]: Expected (6 months)
│  └─ [date removed]: Expected (9 months)
└─ Goal: Confirm PSA remains undetectable

MONTHS 12-24 POST-OP:
├─ PSA testing: Every 3-6 months
├─ Timeline:
│  ├─ [date removed]: 12 months post-op
│  ├─ [date removed]: 15 months post-op
│  ├─ [date removed]: 18 months post-op
│  └─ [date removed]: 24 months post-op
└─ Goal: Confirm sustained undetectable PSA

MONTHS 24+ POST-OP:
├─ PSA testing: Every 6-12 months
├─ Frequency depends on:
│  ├─ Continued undetectable PSA
│  ├─ Patient preference
│  ├─ Physician judgment
│  └─ Risk stratification
└─ Goal: Lifelong surveillance

---

WHAT TO EXPECT AT EACH PSA TEST

[date removed] (Your Next Test)

What is realistic:

MOST LIKELY OUTCOME (85-90% probability):
├─ PSA value: 0.005-0.015 ng/mL
├─ Status: Undetectable or very low
├─ Interpretation: Benign variation, no recurrence
├─ Action: Continue surveillance
└─ Next test: [date removed]

LESS LIKELY OUTCOME (8-12% probability):
├─ PSA value: 0.015-0.050 ng/mL
├─ Status: Detectable but low
├─ Interpretation: Possible benign elevation or early signal
├─ Action: Repeat PSA in 4-6 weeks to confirm trend
└─ Next test: October 2026 (repeat) then November 2026

UNLIKELY OUTCOME (1-3% probability):
├─ PSA value: >0.050 ng/mL
├─ Status: Elevated
├─ Interpretation: Possible early recurrence signal
├─ Action: Urgent repeat PSA, possible imaging
└─ Next test: Immediate repeat (within 2 weeks)

Why these ranges vary (not identical values):

Natural variation sources:

1. LABORATORY MEASUREMENT ERROR
   ├─ CMIA assay precision: ±0.002-0.003 ng/mL
   ├─ Your baseline: 0.009 ng/mL
   ├─ Measurement uncertainty: 0.006-0.012 ng/mL
   └─ This alone explains variation

2. BIOLOGICAL FLUCTUATION
   ├─ Benign prostate inflammation
   ├─ Urinary tract infection
   ├─ Recent ejaculation (affects PSA)
   ├─ Vigorous exercise
   ├─ Digital rectal exam timing
   └─ These cause temporary elevation

3. RESIDUAL BENIGN TISSUE
   ├─ Some benign prostate tissue remains
   ├─